• XBiotech posted a net loss of $5.5 million for three months ended March 31, 2026, narrowing from $10.9 million a year earlier.
• Research and development expense dropped 55% to $5.21 million, driven by a 55% decline in salaries and related costs to $2.84 million.
• General and administrative expense fell 45% to $1.07 million, led by a 64% slide in salaries and related costs to $223,000.
• Cash and cash equivalents totaled $115.5 million at March 31, 2026, down from $155.9 million at March 31, 2025; operating cash outflow widened to $8.97 million.
• Management reiterated it does not expect to generate any revenue in 2026 and ended quarter with 87 employees.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. XBiotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-003419), on May 14, 2026, and is solely responsible for the information contained therein.